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Abstract
Previous studies suggest that there are sex differences in endocannabinoid function and the 
response to exogenous cannabinoids, though data from clinical studies comparing acute 
cannabinoid effects in men and women under controlled laboratory conditions are limited. To 
further explore these potential differences, data from 30 cannabis users (N=18 M, 12 F) who 
completed previous Δ9-tetrahydrocannabinol (Δ9-THC) discrimination studies were combined for 
this retrospective analysis. In each study, subjects learned to discriminate between oral Δ9-THC 
and placebo and then received a range of Δ9-THC doses (0, 5, 15 and a “high” dose of either 25 or 
30 mg). Responses on a drug-discrimination task, subjective effects questionnaire, psychomotor 
performance tasks, and physiological measures were assessed. Δ9-THC dose-dependently 
increased drug-appropriate responding, ratings on “positive” visual analog scale (VAS) items (e.g., 
Good Effects, Like Drug, Take Again), and items related to intoxication (e.g., High, Stoned). Δ9-
THC also dose-dependently impaired performance on psychomotor tasks and elevated heart rate. 
Sex differences on VAS items emerged as a function of dose. Women exhibited significantly 
greater subjective responses to oral drug administration than men at the 5 mg Δ9-THC dose, 
whereas men were more sensitive to the subjective effects of the 15 mg dose of Δ9-THC than 
women. These results demonstrate dose-dependent separation in the subjective response to oral 
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Δ9-THC administration by sex, which might contribute to the differential development of 
problematic cannabis use.
Keywords
marijuana; cannabis; gender; drug-discrimination; self-report
1. Introduction
Cannabis (cannabis sativa, cannabis indica) is one of the most commonly abused drugs in 
the United States. Results from the 2013 Substance Abuse and Mental Health Services 
Administration (SAMHSA) National Survey on Drug Use and Health indicated that 24.6 
million Americans aged 12 or older were recent (past month) illicit drug users, and cannabis 
users accounted for 80% of those individuals (19.8 million). Survey results also 
demonstrated that rates of recent cannabis use were greater in males (12.3 million) relative 
to females (7.5 million), and similarly, that rates of cannabis use disorders (CUDs) were 
greater in males (2.7 million) than females (1.5 million) (SAMHSA, 2014). Further, an 
analysis of recent Treatment Episode Data Set results (SAMHSA, Center for Behavioral 
Health Statistics and Quality, 2013) revealed that more males (223,026) than females 
(82,468) aged 12 or older were admitted to substance abuse treatment for cannabis as the 
primary substance of abuse.
Although males have higher prevalence rates of recent cannabis use, cannabis use disorders, 
and CUD treatment, females appear to be more susceptible to “telescoping,” which is the 
rapid progression from initial use to dependence, and from developing dependence to 
seeking treatment (Ehlers et al., 2010; Hernandez-Avila et al., 2004; Schepis et al., 2011; 
Westermeyer and Beodicker, 2000). For example, the University of California San Francisco 
Family Study of Alcoholism found that women had a shorter time from initial cannabis use 
to cannabis dependence than men (Ehlers et al., 2010). There also appear to be additional 
barriers to successful treatment for cannabis-dependent women. Compared to men, women 
abstaining from cannabis use reported more withdrawal symptoms, which have been linked 
to relapse (Copersino et al., 2010). Women with cannabis use disorders also present with 
higher rates of certain comorbid health problems. For example, upon treatment entry, 
females reported more mood and anxiety disorders (Agrawal et al., 2005; Khan et al., 2013). 
Co-occurring psychiatric and substance use disorders in women are frequently associated 
with poorer psychosocial functioning, medication non-compliance, worse treatment 
outcomes, including drop out, and higher relapse rates (Bernstein, 2000; Reed and Mowbray, 
1999).
Sex differences in the underlying neurobiology of the endogenous cannabinoid system could 
contribute to the differential use and development of dependence observed in men and 
women described above, and have been observed in preclinical studies. For example, 
Castelli and colleagues (2013) found significantly greater cannabinoid CB1 receptor density 
in the prefrontal cortex and amygdala of male rats and ovariectomized female rats compared 
to cycling female rats and ovariectomized female rats receiving replacement estradiol. 
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Region-specific sex differences in cannabinoid receptor mRNA and protein expression, as 
well as endocannabinoid concentrations, that varied as a function of gonadal sex hormones 
have been identified in other brain areas as well (Rodriguez de Fonseca et al., 1994; 
González et al., 2000). Preclinical studies have also found sex differences in the response to 
exogenously administered cannabinoids. For instance, using the behavioral “tetrad” assay of 
cannabinoid effects, Tseng and Craft (2001) demonstrated that several cannabinoid agonists 
including the primary active constituent of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), 
produced greater antinociceptive and motor effects in female rats compared to male rats. In 
another study, Higuera-Matas et al., (2012) found that repeated administration of the 
cannabinoid agonist CP 55,940 to adolescent rats disrupted the normal balance between 
glutamate and GABA transmission to a greater extent in females than in males. A study 
designed evaluate the influence of sex on the reinforcing effects of cannabinoids found that 
female rats acquired self-administration of the cannabinoid agonist WIN 55,212-2 at higher 
rates and with greater intake relative to male and ovariectomized female rats (Fattore et al., 
2007).
Sensitivity to the behavioral, abuse-related effects of cannabis and cannabinoid agonists 
likely contributes to vulnerability to problematic use, but clinical studies that have focused 
on sex differences in these effects are limited. One recent report described a retrospective 
analysis of data combined from four prior studies that examined potential sex differences in 
the behavioral and physiological effects of placebo versus active (3.27%–5.50% Δ9-THC) 
smoked cannabis in frequent cannabis users (Cooper and Haney, 2014). That analysis 
indicated that females were more sensitive to some of the abuse-related subjective effects of 
smoked cannabis (e.g., Take Again and Good Effects) relative to males. There do not appear 
to be any previous studies that have evaluated potential sex differences in the abuse-related 
effects of orally administered Δ9-THC. Such research would be valuable because 
conditioned drug effects, expectancies, and/or peripheral cues could differentially impact the 
response to smoked cannabis in men and women. To this end, the present report combined 
data from seven previous studies to examine possible sex differences in the effects of a range 
of doses of oral Δ9-THC (Lile et al., 2015; 2014; 2012a; 2012b; 2011; 2010a; 2009).
2. Materials and Methods
In each of the studies included in the present analysis, the discriminative-stimulus, subject-
rated, performance and physiological effects of a range of oral Δ9-THC doses (0, 5, 15 and a 
“high” dose, either 25 or 30 mg) were determined. In addition, each study tested various 
other drug conditions either alone or alone and in combination with Δ9-THC (see below), 
but only data from sessions in which Δ9-THC was administered alone were included in the 
present analysis. When a subject completed more than one study, only data from the first 
study that the subject completed were included here.
2.1 Subjects
Data from thirty subjects (18 males and 12 females) who self-reported current cannabis use 
were analyzed. To maximize the number of subjects who could be included, and considering 
the retrospective nature of the analysis, males and females were not matched on cannabis 
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use; however, cannabis use (i.e., days per week and years of use) did not significantly differ 
as a function of sex (see section 2.3). Subjects were predominantly White (1 Black, 1 White-
Hispanic, 1 multiracial White/Asian) adults with a history of cannabis use who were 
recruited from the local community. Subjects completed demographic, drug-use history, and 
medical history questionnaires, as well as medical screens. Individuals with current or past 
histories of Axis I disorders according to DSM-IV criteria (American Psychiatric 
Association, 2000), including substance dependence other than nicotine, were excluded from 
participation. Substance abuse was not an exclusion criterion. No recent illicit drug use 
except for cannabis was detected during screening with two exceptions; one subject tested 
positive for cocaine and one subject tested positive for benzodiazepines during the medical 
screening. The Institutional Review Board of the University of Kentucky Medical Center 
approved the studies and the informed consent document.
2.2 General Procedures
All subjects were enrolled as outpatients at the University of Kentucky. They completed two 
drug-free practice sessions to become familiarized with the procedures prior to completing 
the study proper. Subjects were informed that they would receive various drugs including 
placebo and Δ9-THC but were blind to the dose and order of administration. They were 
asked to abstain from illicit drugs other than cannabis, and to abstain from over-the-counter 
medications, other than non-steroidal anti-inflammatory analgesics, for the duration of the 
experiment. Subjects were also asked to abstain from any drug use on the day of 
experimental sessions to avoid potentially unsafe drug interactions. In addition, subjects 
were asked to refrain from food or caffeine intake for 4 h prior to each experimental session, 
or alcohol for 12 h prior to and following each experimental session. Subjects who smoked 
tobacco cigarettes were also asked to abstain from smoking the morning of each session, but 
were allowed to smoke a single tobacco cigarette upon arrival to the laboratory to avoid 
testing under conditions of nicotine withdrawal, but not again until the session had ended. 
There was no indication of nicotine withdrawal in these subjects.
Experimental sessions were conducted at a fixed time, Monday through Friday, and lasted 
approximately 6.5–7.5 h; subjects typically participated in 1 to 5 sessions per week. At the 
beginning of each session, breath and urine tests to assess substance use and pregnancy were 
conducted. Urine samples were negative for recent use of drugs other than cannabis and 
those administered experimentally. Pregnancy screening results were negative throughout 
the studies.
At session intake, subjects also completed a modified version of the U.S. Department of 
Transportation Drug Evaluation and Classification Screening (walk and turn, timed one-leg 
balance or Romberg balance, time interval reproduction and the finger-to-nose tests; [Toland 
and Green, 1991]) and were observed by trained research staff for signs of cannabis 
intoxication (e.g., bloodshot, glassy eyes). Subjects were also asked to self-report their 
cannabis use in the past 24 h. No cannabis intoxication was detected during intake 
throughout the studies as verified by trained research staff and self-report. Furthermore, 
because oral Δ9-THC was not administered for approximately 30–60 min after arrival to the 
laboratory and considering that plasma Δ9-THC concentrations typically peak within 10 min 
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and return to near-baseline levels within 1 h of smoked administration (Huestis et al., 1992), 
the impact of any undetected cannabis use prior to the start of the session on study outcomes 
would have been minimal. Subjects were reassessed at the end of the session for possible 
intoxication and/or residual drug effects prior to release. In addition, subjects were required 
to report no further drug effects. Occasionally subjects were retained at the laboratory 
beyond the scheduled session time until residual drug effects dissipated.
2.3 Drug-Discrimination Procedure
Subjects learned to discriminate between a “Drug X” condition (i.e., 25 or 30 mg Δ9-THC) 
and a “Not Drug X” condition (i.e., placebo) as described previously in detail (e.g., Lile et 
al., 2009). During a sampling phase, subjects received the training dose of Δ9-THC (25 or 30 
mg), identified by a unique letter code (e.g., Drug X). During a control phase, subjects were 
required to correctly identify when they received placebo (i.e., Not Drug X) or the training 
dose of Δ9-THC (Drug X). The criterion for having acquired the discrimination was ≥ 80% 
correct responding on the final assessment of the drug-discrimination task for four 
consecutive sessions (two sessions each for the Drug X and Not Drug X conditions). Finally, 
a test phase was conducted in which subjects received placebo, Δ9-THC (5, 15 and 25 or 30 
mg) and a range of doses of various drugs alone (methylphenidate, hydromorphone, 
triazolam and nabilone) or alone and in combination with Δ9-THC (i.e., nabilone, tiagabine, 
baclofen, diazepam, and gabapentin). Each drug dose or dose combination was administered 
once, with the exception of the training conditions, which were administered throughout the 
test phase to monitor and provide feedback about drug-discrimination performance. The 
present analysis included data only from sessions in which Δ9-THC and placebo were 
administered alone.
2.4 Outcome measures
2.4.1. Drug-Discrimination Task—Two circles labeled Drug X and Not Drug X and 
associated counters were displayed on a computer screen. Button presses increased the 
counter for a particular circle according to a fixed-interval 1-s schedule for 60 s (no change-
over delay). At the end of the final assessment, subjects were informed whether it was a 
control or a test session. During control sessions, points accumulated on the correct option 
were exchangeable for money (up to approximately $50.00/session). During test sessions, 
when drugs and/or doses other than the control conditions were administered, subjects 
earned the average from all previous sessions in which control conditions were tested. The 
dependent variable for this task was the percent responding on the drug-appropriate option at 
the final assessment of the session.
2.4.2. Visual Analog Scale (VAS) Subject-Rated Drug-Effect Questionnaire—
Subjects rated 18 items (see Lile et al., 2012a) that assessed general “positive” (e.g., Good 
Effects, Like Drug) and “negative” (e.g., Bad Effects, Nauseated) drug effects, as well as 
items specific to cannabis intoxication (e.g., Stoned). Subjects rated items presented 
individually on the computer by marking a 100-unit line anchored on the extremes by “Not 
At All” and “Extremely.”
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2.4.3. Performance Tasks—These tasks were chosen because prior research has found 
them to be sensitive to the impairing effects of oral Δ9-THC (Hart et al., 2005; Kamien et al., 
1994) and smoked cannabis (Heishman et al., 1989; Kelly et al., 1993; 1990; Wilson et al., 
1994). Subjects did not receive additional compensation based on task performance.
2.4.3.1. Repeated Acquisition of Response Sequences Task (RA task): During the initial 
acquisition component, subjects pressed 4 keys (1, 3, 7 and 9) on a numeric keypad to learn 
a new, randomly-determined 10-response sequence (a “chain”) for 180-s. When a correct 
key in the sequence was pressed, a “position” counter on the screen increased by 1. When 
the tenth and final key in the sequence was pressed, a “points” counter increased by one, and 
the position counter reset. A 60-s performance component of this task, in which the 10-
response sequence remained the same across trials, followed the acquisition component. The 
primary dependent measures for this task were the number of chains completed (i.e., 
accuracy) and the total number of responses emitted (i.e., response rate).
2.4.3.2. Digit-Symbol-Substitution Test (DSST): A modified version of the computerized 
DSST was used (McLeod et al., 1982). Briefly, subjects used a numeric keypad to enter the 
geometric pattern associated with one of nine patterns identified on a given trial for 90s. The 
dependent measures were the number of patterns the subject entered correctly (i.e., trials 
correct; accuracy) and the total number of patterns entered (i.e., trials completed; response 
rate).
2.4.3.3. Time Reproduction Task: Two time periods, 30, and 60s and were presented. 
Subjects responded to start a timer, and held down the response key until they believed that 
the interval had elapsed.
2.4.4. Physiological Indices
2.4.4.1. Heart Rate and Blood Pressure: Heart rate and blood pressure were recorded 
using an automated monitor (DINAMAP, Johnson and Johnson, Alexandria, TX).
2.4.4.2. Temperature: An infrared thermographic scanner (Derma-Temp, Exergen 
Corporation, Watertown, MA) was used to measure skin temperature on the tip of the index 
finger. An electronic thermometer was used to measure oral temperature.
2.5. Drug Administration
All drug conditions were administered in a double-blind fashion. Doses were prepared by 
encapsulating commercially available capsules of dronabinol (Δ9-THC in sesame oil, Solvay 
Pharmaceuticals, Marietta, GA) in opaque green size 00 capsules. Cornstarch was used to 
fill the remainder of all capsules. Placebo capsules contained only cornstarch. Capsules were 
prepared by the University of Kentucky Medical Center Investigational Drug Service 
Pharmacy. For reference, the acute recommended Δ9-THC dosing range in adults for 
appetite stimulation and the prevention of nausea and vomiting is 2.5 to 20 mg (Marinol® 
product information).
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2.6. Data Analyses
Demographic variables (weight, age, cannabis, alcohol, cigarette, and caffeine use history) 
were compared using two-sample t-tests. For the high dose (i.e., 25 or 30 mg) Δ9-THC and 
placebo conditions, data were averaged across the sessions in which these conditions were 
presented during the test phase. Raw data from the self-reported drug-effect questionnaires, 
performance tasks and physiological measures were analyzed for each drug as area-under-
the curve (AUC) from data collected hourly for five hours after Δ9-THC administration. In 
order to 1) incorporate data from all time points, 2) more closely correspond with the 
analytical strategy and 3) facilitate interpretation of the figures (i.e., provide values that 
approximate raw data), AUC values were calculated and then divided by the number of post-
drug data points used to calculate AUC for graphical representation.
AUC outcomes corresponding to performance and physiological measures were analyzed 
using linear mixed models. Skewed values for AUC outcomes, corresponding to items on the 
Visual Analog Scale, were handled by using generalized linear mixed modeling. 
Specifically, AUC values were rounded up to the closest integer value, and generalized 
poisson models for overdispersed count data were utilized. All models were mixed, as 
random subject effects were used to account for subjects contributing an AUC outcome at 
each dose.
Results for overall main effects or interactions of Δ9-THC and Sex in a given model were 
judged by a Type III F test. Significant effects were followed by pairwise comparisons of 
individual data points, with the likelihood of Type I error minimized by limiting 
comparisons to planned pairs. More specifically, if a main effect of Δ9-THC attained 
statistical significance, planned comparisons of active drug doses to placebo were 
conducted; if an interaction of Δ9-THC and Sex attained statistical significance, each dose of 
Δ9-THC was compared across Sex. For all measures, effects were considered significant for 
p ≤ 0.05. Analyses were conducted using SAS v9.4 (SAS Institute Inc., Cary, NC).
3. Results
3.1. Demographics
Table 1 presents the age, weight and self-reported daily caffeine and cigarette use, weekly 
alcohol and cannabis use, and number of years using cannabis, for male and female subjects. 
Men and women did not differ on demographic variables or substance use patterns, except 
that the men were significantly older.
3.2. Drug-Discrimination Task
Men and women did not differ significantly in terms of the number of trials needed to 
acquire the Δ9-THC discrimination (mean of 4.89 and 4.92 trials, respectively). A main 
effect of Δ9-THC was detected for percentage of drug appropriate responding (F3, 84 = 
41.56, p < 0.01). The effects of Δ9-THC on percentage of drug appropriate responding did 
not vary significantly as a function of Sex.
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3.3. Subject Ratings
The interaction of Δ9-THC and Sex attained statistical significance for nine items from the 
VAS: Any Effect (F3, 84 = 5.53, p < 0.01), Confused/Difficulty Concentrating (F3, 84 = 5.21, 
p < 0.01), Good Effect (F3, 84 = 6.28, p < 0.01), High (F3, 84 = 7.41, p < 0.01), Like Drug 
(F3, 84 = 6.36, p < 0.01), Pay For (F3, 84 = 4.41, p < 0.01), Stimulated (F3, 84 = 5.12, p < 
0.01), Stoned (F3, 84 = 7.56, p < 0.01) and Take Again (F3, 84 = 4.68, p < 0.01). Figure 1 
presents the items Good Effect, High, Pay For, Stoned, Like Drug and Take Again. As 
illustrated in that figure, Δ9-THC dose-dependently increased ratings on each of these items. 
Comparisons of sex at each Δ9-THC dose revealed that, in general, women had a greater 
subjective response following administration of 5 mg Δ9-THC compared to men, although 
that dose did not engender subjective effects that were significantly greater than placebo in 
either sex. In contrast, men were more sensitive to the subjective effects of the 15 mg Δ9-
THC dose. More specifically, 15 mg Δ9-THC significantly increased ratings on those VAS 
items in men only, and for the item Like Drug, male subjects’ ratings were significantly 
greater than those of female subjects. Sex differences also emerged following administration 
of placebo for the items Confused/Difficulty Concentrating, Good Effect, High, Pay For, and 
Stoned, with women reporting exhibiting a greater subjective response following placebo 
administration, but no differential responding by sex at active doses.
Δ9-THC also dose-dependently increased ratings of Bad Effect, Dizzy/Lightheaded, 
Forgetful, Hungry, Shaky/Jittery, Suspicious, and Thirsty (F’s3,84 = 3.03–13.21, p’s < 0.05), 
but these effects did not vary significantly as a function of Sex.
3.4. Physiological Effects
Main effects of Δ9-THC (F3, 84 = 23.69, p < 0.01) and Sex (F3, 84 = 6.80, p < 0.05) were 
detected for heart rate. The highest doses of Δ9-THC significantly elevated heart rate in male 
and female subjects relative to placebo. Heart rate was significantly higher in women after 
administration of the 5 mg and “high” doses of Δ9-THC, but also following placebo, 
suggesting that the differential heart rate was independent of Δ9-THC dose (Figure 2).
A main effect of Sex was found for skin temperature (F3, 84 = 6.37, p < 0.05). Women had 
lower skin temperature following administration of the 5 mg and “high” doses of Δ9-THC as 
well as placebo. Δ9-THC did not influence skin temperature (Figure 2). Systolic blood 
pressure, diastolic blood pressure and oral temperature did not vary as a function of Δ9-THC 
or Sex.
3.5. Performance Effects
3.5.1. Digit-Symbol Substitution Task—Δ9-THC dose dependently impaired accuracy 
on the DSST as measured by the number of correct trials (F3, 84 = 3.25, p < 0.05); the 
number of trials completed (i.e., rate) was not impacted by Δ9-THC (data not shown). The 
effects of Δ9-THC on the DSST did not vary significantly as a function of Sex.
3.5.2. Repeated Acquisition of Response Sequences Task—Δ9-THC dose 
dependently impaired performance on the RA task as measured by the number of chains 
completed (accuracy; F3, 84 = 6.99, p < 0.01) and the total number of responses emitted 
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(rate; F3, 84 = 6.98, p < 0.01; data not shown). The effects of Δ9-THC on the RA Task did not 
vary significantly as a function of Sex. In addition, Δ9-THC dose dependently impaired 
accuracy on the performance component of the RA task (F3, 84 = 2.86, p < 0.05), but the 
effects of Δ9-THC did not vary significantly as a function of Sex (data not shown). Neither 
Δ9-THC nor Sex impacted rate on the performance component of the RA task.
4. Discussion and Conclusions
The present study demonstrated dose dependent sex differences in the subjective response to 
oral Δ9-THC administration. Women exhibited greater subjective responses to oral drug 
administration than men at the 5 mg Δ9-THC dose, whereas men were more sensitive to the 
subjective effects of the 15 mg dose of Δ9-THC than women. These results differ from a 
prior retrospective analysis that examined sex differences in the response to acutely 
administered smoked cannabis in frequent cannabis smokers and found that women were 
more sensitive to abuse-related subjective effects relative to men on some drug effect 
questionnaire items (Cooper and Haney, 2014). The reasons for the discrepancies between 
the results of that study and the present study are unknown, but could be due to procedural 
factors such as route of administration, the amount of Δ9-THC delivered, testing multiple 
Δ9-THC doses versus a single Δ9-THC concentration per study, and/or subject differences 
such as cannabis use history and race/ethnicity. For example, the Cooper and Haney study 
administered a single active concentration of smoked cannabis (ranging from 3.27%–5.50% 
Δ9-THC, varying by study) containing other phytocannabinoids, whereas the present study 
used a range of Δ9-THC doses (5–30 mg), administered orally. In addition, participants in 
the prior analysis were predominantly Black and reported smoking cannabis at least four 
times per day, approximately 7 days a week in the four weeks prior to screening. In contrast, 
participants in the present analysis were predominantly White and reported smoking 
cannabis an average of 4.5 days per week in the month prior to screening. A prospective 
study to test potential sex differences of cannabinoids administered via commonly used 
routes (i.e., oral and smoked) in a sample with greater racial/ethnic diversity would be useful 
to disentangle whether these factors account for the discordant results from these 
retrospective analyses.
The pattern of differential sensitivity to low and high doses of Δ9-THC administration as a 
function of sex observed in the present analysis is reminiscent of the response to Δ9-THC 
observed in frequent vs. infrequent cannabis users (Kirk and de Wit, 1999). In that study, 
frequent users (self-reported cannabis use greater than 100 times) reported increased ratings 
of “feel drug” at the lower dose compared to the infrequent users (self-reported cannabis use 
less than 100 times). However, at the higher dose, infrequent users reported increased ratings 
of “feel drug” compared to frequent users. The present study suggests that, like frequent 
users, females may be more likely to report drug effects at lower doses but are more tolerant 
to higher doses. Greater tolerance to cannabinoid effects in women could result in more 
frequent use or use of a larger amount of cannabis, which might be a contributing factor to 
the telescoping effect observed in women.
The underlying factors contributing to sex differences in the abuse-related subjective effects 
of smoked cannabis and Δ9-THC are unknown. The differential response does not appear to 
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be due to pharmacokinetic factors, as the absorption, disposition, metabolism and excretion 
of Δ9-THC following oral and intravenous administration did not differ in men and women 
(Wall et al., 1983). Similarly, although fixed doses were administered in each study that was 
included in the present analysis, male and female subjects did not differ significantly in 
weight, suggesting that functional dose differences cannot account for the separation in 
subjective effects between men and women.
Another possible explanation is that the composition of the endogenous cannabinoid system 
is distinct in women, as suggested by preclinical studies (e.g., Castelli et al., 2013; González 
et al., 2000; Rodriguez de Fonseca et al., 1994). Further, the effects of cannabinoids in 
women could be subject to dynamic changes as a function of fluctuating gonadal sex 
hormones (i.e., estrogen and progesterone). For example, CB1 receptor density in the medial 
basal hypothalamus and expression in the anterior pituitary varies across the estrous cycle in 
rodents (Rodriguez de Fonseca et al., 1994). Further, Craft and Leitl (2008) followed up on 
earlier work that compared cannabinoid-induced antinociception in male and female rats, 
and demonstrated that estrogen administration enhanced the antinociceptive effects of Δ9-
THC in ovariectomized females. A more recent study that assessed the influence of gonadal 
sex hormones on withdrawal from repeated Δ9-THC administration in rats suggested that 
estradiol and progesterone could promote the development of dependence, whereas 
testosterone might be protective (Marusich et al., 2015).
Some previous clinical studies have also demonstrated that menstrual cycle phase, gonadal 
sex hormone levels and the administration of these hormones are associated with altered 
abuse-related behavioral effects of psychoactive drugs. For example, two studies that tested 
d-amphetamine across menstrual cycle phase found that women rated certain positive 
subject-rated drug effect questionnaire items higher during the early-to-mid follicular phase, 
when only estrogen levels are increasing, relative to the luteal phase, when both estrogen and 
progesterone are elevated (Justice and de Wit, 2000a; White et al., 2002). Similarly, another 
study showed that administration of exogenous estradiol when endogenous hormone levels 
were low enhanced the subjective and discriminative-stimulus effects of d-amphetamine 
(Lile et al., 2007). In a series of studies, Babalonis and colleagues found that the 
interoceptive effects of triazolam were affected by menstrual cycle phase (2008) and 
concurrent progesterone administration (2011). Only a few clinical studies have examined 
potential interactions of cannabis with the menstrual cycle. In one study, self-reported 
cannabis use did not vary with cycle phase (Griffin et al., 1986). A second study that 
examined the effects of controlled administration of smoked cannabis containing a low 
concentration (1.8%) of Δ9-THC in women on mood and heart rate did not find significant 
differences on any measure across menstrual cycle phases (Lex et al., 1984). Worth noting, 
however, is that clinical studies with abused drugs other than cannabis have not always 
revealed hormone-related differences in subjective effects (e.g., Justice and de Wit, 2000a, 
2000b; Mendelson et al., 1999). Also worth noting is that the data in the present analysis and 
previous studies that have reported sex differences in the subjective response to cannabinoids 
(Cooper and Haney, 2009, 2014) were collected without regard to menstrual cycle phase, 
which might have limited the ability to detect sex differences, and more specifically, the 
influence of gonadal sex hormones, on cannabinoid effects. Further research would be useful 
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to better understand the relationship between cycle phase, hormones, and cannabinoid 
effects.
The present analysis did not reveal sex differences in the number of trials needed to acquire 
the Δ9-THC discrimination or in the Δ9-THC discrimination dose-response curves. 
Consistent with these results, two previous retrospective analyses using drug discrimination 
data did not find sex differences in the discriminative-stimulus effects of triazolam 
(Vansickel et al., 2006) or d-amphetamine (Vansickel et al., 2007). As described above, in 
drug discrimination studies subjects must acquire the discrimination before continuing to a 
test phase in which full dose-response curves are determined. This training provides similar 
recent behavioral and pharmacological histories, which are important determinants of drug 
effects (e.g., Lile et al., 2000; Nader and Reboussin, 1994), and which might have limited 
the ability to detect individual differences in drug effects in the test phase (Kamien et al., 
1995; Singha et al., 1999). However, the present study and the analysis of the combined d-
amphetamine discrimination data (Vansickel et al., 2007), which had approximately 
equivalent sample sizes (N = 30 and 27, respectively), detected sex differences for some of 
the subject-rated drug-effects questionnaire items. Together, these results demonstrate that 
sex differences in the subjective response to drugs can be sufficiently robust as to emerge 
despite the influence of the recent discrimination training.
Sex differences were also observed for heart rate and skin temperature after administration 
of two active doses of Δ9-THC. However, similar differences between males and females 
were also found following placebo administration, suggesting that these results were due to 
baseline physiological differences rather than Δ9-THC. The observation that women had 
elevated heart rate and lower skin temperature relative to men is consistent with previously 
documented differences in women and men for these physiological outcomes (Christensen et 
al., 2012; Ryan et al., 1994; Umetani et al., 1998). Another possibility is that chronic 
cannabis administration might result in further sex-based separation in baseline heart rate 
and skin temperature, considering that these measures are sensitive to acute cannabinoid 
administration (e.g., Lile et al., 2010b).
A notable limitation of the present analysis is that, due to the retrospective nature of the 
design, groups were not matched on all cannabis use variables. At the time of study 
screening, subjects reported the number of days per week and the total number years of 
cannabis use. However, the total number of cannabis use instances per week and the total 
lifetime instances of use, which could impact sensitivity to the effects of oral Δ9-THC, were 
only available for a subset of subjects who participated in the later studies, and were 
therefore not included in the analysis. An exploratory analysis of potential sex differences in 
this smaller subset of subjects suggested that the present findings were not due to group 
differences in the number of weekly cannabis use instances (N = 6F, 16.83 ± 5.50 [MEAN ± 
SEM] uses, 13M, 9.08 ± 2.09; t = 1.62, ns) or estimated total lifetime cannabis use (N = 9F, 
4330 ± 3655, 12M, 4597 ± 1825; t = 0.07, ns).
In conclusion, dose-dependent sex differences in the subjective response to oral Δ9-THC 
were observed. These sex differences were apparent despite the similar recent behavioral 
and pharmacological histories imposed by the drug-discrimination training, and despite the 
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fact that testing was done irrespective of menstrual cycle phase. The existing clinical studies 
of sex differences in cannabinoid effects under controlled laboratory conditions are limited 
and the results are mixed, suggesting that further research is warranted. A better 
understanding of how differences in the subjective response to cannabis in women might 
contribute to their more rapid progression to dependence is needed. Further, a more 
comprehensive investigation into sex-related factors in the etiology of cannabis use disorders 
should be conducted in an effort to address the unique treatment barriers for women, such as 
comorbid psychiatric disorders and greater cannabis withdrawal signs and symptoms.
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Highlights
A retrospective analysis using data from prior drug discrimination studies in 
humans was conducted to examine potential sex differences in the acute 
effects of Δ9-THC.
Subjects received a range of Δ9-THC doses (0, 5, 15 and a “high” dose of 
either 25 or 30 mg); drug effects were assessed using drug discrimination, 
subjective effects, cognitive/psychomotor performance and physiological 
measures.
Dose-dependent sex differences in some of the subjective effects of oral Δ9-
THC administration were found, which might contribute to the differential 
development of dependence in men and women.
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Figure 1. 
Visual Analog Scale ratings of Good Effect, High, Pay For, Stoned, Like Drug and Take 
Again as a function of Δ9-THC dose and Sex. The x-axis represents Δ9-THC dose in mg; PL 
denotes placebo. Squares indicate female subjects (N=12) and circles indicate male subjects 
(N=18). Filled symbols indicate values that are significantly different from placebo. 
Asterisks indicate significant sex differences at each dose condition. The y-axis represents 
VAS data in area-under-the-curve (AUC) values. In order to incorporate data from all time 
points and more closely correspond with the analytical strategy data are presented as area-
under-the-curve (AUC) values divided by the number of post-drug data points used to 
calculate AUC. Unidirectional brackets indicate 1 SEM.
Fogel et al. Page 17
Pharmacol Biochem Behav. Author manuscript; available in PMC 2018 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 2. 
Peak heart rate (maximum value) and skin temperature (minimum value) as a function of Δ9-
THC dose and Sex. All other details are as in Figure 1.
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Table 1
Subject Demographic Characteristics: Means, standard deviations, and t-values from independent samples t-
tests. Bold values indicate a significant difference (p < 0.05).
Demographics Male (N = 18) Female (N = 12) t-value (df = 28)
Age 23.39 ± 0.86 21.08 ± 0.68 2.10
Weight (kg) 78.90 ± 4.25 68.98 ± 4.22 1.59
Years of Cannabis Use 7.47 ± 1.19 4.41 ± 0.93 1.41
Cannabis Use (days per week) 4.5 ± 0.54 4.63 ± 0.72 1.85
Cigarette Use (# per day) 3.28 ± 1.41 2.67 ± 1.65 0.30
Alcohol Use (days per week) 1.93 ± 0.33 1.40 ± 0.35 1.08
Caffeine Use (mg per day) 161.61 ± 60.41 113.17 ± 48.64 0.58
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